Astellas on generic threat: ”It’s part of the game”
One of the best-selling drugs from the Japanese drug group Astellas is now facing generic competition. It is part of the game, says the management of the company’s Scandinavian unit, adding that it does not feel noteworthy competition from its rival Veloxis.
BY MARTIN HAVTORN PETERSEN
Earlier this month, an advisory committee from the European Medicines Agency (EMA) recommended approval of a generic version of Astellas Pharma’s drug Advagraf for prevention and treatment of organ rejection.
Allerede abonnent?Log ind her
Læs hele artiklen
Få adgang i 14 dage for 0 kr. Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
Med din prøveperiode får du:
Få fuld adgang til dig og dine kollegaer
Start et gratis virksomhedsprøveabonnementRelaterede artikler
New generic could put pressure on Veloxis
For abonnenter
Veloxis hires chief scientific officer from BMS
For abonnenter
